PlaqueTec and Babraham Institute partner for treatment of coronary heart disease
CAD is responsible for around 68,000 deaths per year in the UK
Read More
Tag: coronary artery disease
Brilinta hits targets in PhIII cardiovascular/diabetes trial
AstraZeneca’s Brilinta has been found to reduce cardiovascular events in patients with coronary heart disease and diabetes but no prior heart attack or stroke.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
